2018. Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study. SKIN The Journal of Cutaneous Medicine. 2, S1 (Feb. 2018), S45. DOI:https://doi.org/10.25251/skin.2.supp.45.